Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MP1032 in moderate to severe chronic plaque psoriasis
NCT02908347Phase 2Completed
- Sponsor
- MetrioPharm AG
- Start
- May 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in plaque psoriasis comparing MP1032 with Placebo (2 arms). Primary endpoints: Treatment Emergent Adverse Events, Pharmacokinetics - Plasma Concentrations at Day 43 and 2 more. Started May 2016; status: completed.
02
Drugs
mp1032
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02908347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02908347.